Salivary Gland Infection Market

Roughly 1.34 million people a year reach a clinician with an inflamed salivary gland, and Douglas Insights counts 1.339 million of those as treated episodes worth an average USD 331.7 each, which sets the salivary gland infection market at USD 444.1 million in 2025 (1.339 million × USD 331.7 = USD 444.1 million). Revenue climbs to USD 695.0 million by 2035, a 4.58% annual CAGR built from 2.41% episode growth and 2.12% price growth. The latest public-health signal arrived on 30 July 2026, when the UK Health Security Agency reported 48 laboratory-confirmed mumps infections in England for January to March 2026, up 71.4% on the previous quarter’s 28. Anti-infective sales here connect to the wider pharmaceuticals coverage, while episode counting and pricing follow the Douglas Insights research methodology.

Who presents with an inflamed salivary gland, and how does the sialadenitis pathway run?

Four conditions feed 1.339 million treated salivary gland infection episodes: acute bacterial sialadenitis (36.9%), obstructive sialolithiasis (25.3%), viral and mumps parotitis (24.6%) and chronic recurrent sialadenitis (13.2%). Acute bacterial sialadenitis supplies 494,060 episodes. A 2014 American Family Physician review reports Staphylococcus aureus cultured in 50% to 90% of acute cases, which is why an oral beta-lactam course sits at the start of most pathways.

Stones give the salivary gland infection pathway its procedural tail. A Danish register study counted 7.27 to 14.10 sialolithiasis cases per 100,000 person-years, and 80% to 90% of stones lodge in the submandibular gland. Douglas Insights tallies 338,746 obstructive episodes worldwide in 2025.

Mumps is the viral leg: 329,373 episodes, weighted to China, India and other markets with lower two-dose MMR coverage. Chronic recurrent cases add 176,737 episodes and most of the repeat imaging. Patients typically move from primary care or emergency triage, to ultrasound, to antibiotics plus hydration and sialogogues, and only then to sialendoscopy or gland removal.

Why are sialadenitis episodes rising faster than population growth?

Episodes grow 2.41% a year against world population growth below 1%, and four forces explain the gap. Douglas Insights splits that 2.41-point volume leg into 0.97, 0.83, 0.43 and 0.18 points.

Ageing and polypharmacy contribute 0.97 points. Salivary flow falls with age and with anticholinergic, diuretic and antidepressant use, and dehydrated older inpatients are the classic acute suppurative parotitis group. A Saudi multicentre record study published in 2026 counted 1,340 parotitis cases across 2015 to 2023, while older literature puts acute suppurative parotitis at 0.02% to 0.04% of hospital admissions. Each extra cohort of over-75s lifts salivary gland infection episodes without any change in incidence per person.

Ultrasound-first diagnosis adds 0.83 points. Point-of-care ultrasound in emergency departments and ENT clinics, part of the device base tracked in our Color Ultrasound Diagnostic Equipment Market report, now finds stones and abscesses that once went uncoded as “facial swelling”. The Danish data show the effect clearly: all-case sialolithiasis incidence of 14.10 per 100,000 is almost double the 7.27 rate for visually confirmed stones, and nearly three times the 5.5 per 100,000 reported for hospital-admitted cases from 2000 to 2010.

Mumps among adolescents and adults contributes 0.43 points. The 30 July 2026 UKHSA bulletin found 85% of England’s 48 first-quarter cases in people aged 15 or older, a group in which waning vaccine immunity is documented. In the United States, the CDC listed 157 mumps cases across 31 jurisdictions as of 10 September 2026. China reported 300,358 cases in 2019 at 21.30 per 100,000 before pandemic distancing cut the count to 120,125 in 2021, and a rebound toward pre-2020 levels supplies most of the mumps volume in this salivary gland infection model.

Wider access to ENT care in Asia Pacific, Latin America and the Gulf adds the final 0.18 points. More county hospitals in China and India now record sialadenitis as a coded diagnosis rather than a generic infection, which pulls previously invisible episodes into the paid market. Asia Pacific supplies 775,070 salivary gland infection episodes in this model, yet its USD 152 average episode value is about a quarter of Europe’s USD 588.

The four drivers do not carry equal weight in value. Ageing patients are the most expensive, since suppurative parotitis in a frail inpatient can mean several days on intravenous antibiotics, while a teenage mumps case costs little beyond a clinic visit. That gap is why a 0.43-point mumps contribution moves revenue far less than the 0.97-point ageing contribution.

Where do sialadenitis treatment dollars concentrate, and which region grows fastest?

North America holds USD 165.3 million, or 37.2% of 2025 salivary gland infection revenue, on just 8.4% of episodes, because each case averages USD 1,462. Douglas Insights expects the region to reach USD 238.6 million by 2035 at 3.74% a year.

Europe follows at USD 119.4 million and grows 3.36% a year to USD 166.2 million, held back by high MMR coverage and capped hospital tariffs. Asia Pacific is the fastest-growing region at 6.52% a year, rising from USD 117.8 million to USD 221.5 million, because it carries 57.9% of world episodes and its average episode value is climbing from USD 152 as imaging and sialendoscopy spread through tertiary hospitals. Latin America moves from USD 21.6 million to USD 35.4 million at 5.07%. The Middle East and Africa grows from USD 20.0 million to USD 33.3 million at 5.23%.

The wildcard is China’s mumps cycle. A return to the 2019 rate of 21.30 per 100,000 would add more salivary gland infection episodes than the entire European obstructive caseload.

Which sialadenitis treatment segment makes the money, from antibiotics to sialendoscopy?

Antibiotics and anti-infectives lead with 31.7% of salivary gland infection revenue, USD 140.8 million in 2025, because almost every bacterial and chronic episode receives at least one course.

Antibiotics and anti-infectives earn their USD 140.8 million on volume, not price: generic amoxicillin-clavulanate, clindamycin and cephalosporin courses cost little, but they reach roughly 1.2 million episodes. Imaging and diagnostics take 22.9%, or USD 101.7 million, because ultrasound is now the default first test and sialography or cone-beam CT, both part of the Diagnostic Imaging Market, follows in recurrent cases. Sialadenectomy surgery holds USD 81.3 million on only a small number of high-ticket operations, and grows just 1.58% a year as gland-sparing techniques take its patients.

Sialendoscopy and gland-preserving procedures are the fastest-growing segment at 9.14% a year, rising from USD 78.2 million to USD 187.5 million and overtaking antibiotics by 2035. Interventional sialendoscopy, basket retrieval, balloon dilation and intraductal lithotripsy clear stones and strictures while keeping the gland, and US claims data showed sialoendoscopy rates tripling from 0.13 to 0.42 per 100,000 between 2007 and 2013. Supportive care and sialogogues, the hydration, gland massage and lemon-drop or vitamin C lozenge regimens that a 2014 review lists for acute cases, account for 9.5% and USD 42.2 million.

How is salivary gland infection spending split between inpatient wards, clinics and office-based ENT?

Outpatient clinic care takes 47.1% of salivary gland infection revenue, USD 209.2 million, because most acute bacterial and mumps episodes are diagnosed and treated without admission. Hospital inpatient care holds 34.8%, or USD 154.5 million, concentrated in elderly suppurative parotitis, abscess drainage and gland excision. Office-based ENT accounts for 18.1%, or USD 80.4 million, and is the fastest-moving channel: a 2022 American Journal of Otolaryngology analysis found mean sialendoscopy charges of USD 1,298 in the office against USD 5,560 in the operating room.

What headwinds slow sialendoscopy uptake and parotitis caseloads?

Three headwinds remove 0.97 points from gross salivary gland infection growth, cutting the base case from a gross 5.55% to the 4.58% revenue CAGR.

Vaccination keeps mumps contained in high-income markets and removes 0.29 points. The ECDC annual report counted 2,963 mumps cases across 27 EU/EEA states in 2023, a notification rate of only 0.7 per 100,000. England logged just 20 confirmed infections in July to September 2025.

Sialendoscopy training and capital remain a bottleneck that removes 0.22 points. Scopes, video towers, baskets and lasers are a capital purchase, and the learning curve keeps salivary gland infection procedures in specialist centres. US data showed 87.5% of insured sialadenitis and sialolithiasis patients in a 5,111-person cohort still went to sialadenectomy rather than sialendoscopy.

Generic antibiotic deflation removes 0.46 points from the price leg. DailyMed lists 273 amoxicillin-clavulanate labels, and that crowded field keeps the most-used salivary gland infection drug cheap in every region.

How much does a treated sialadenitis episode cost, from amoxicillin-clavulanate courses to operating-room sialendoscopy?

A treated salivary gland infection episode averages USD 331.7 worldwide in 2025, but realised values range from USD 131 in the Middle East and Africa to USD 1,462 in North America.

Europe averages USD 588 per episode and Latin America USD 228. A generic oral antibiotic course sits in the USD 8 to USD 60 band at pharmacy level in most markets, and a diagnostic ultrasound adds roughly USD 40 to USD 250. Sialendoscopy is where value jumps. US charges average USD 1,298 for an office procedure and USD 5,560 in the operating room, and open sialadenectomy with an overnight stay sits higher still. Douglas Insights puts the average price per episode at USD 409.1 by 2035, a 2.12% annual rise driven by procedure mix rather than list-price inflation.

Which FDA 510(k) and drug approval rules govern sialendoscopes and salivary gland anti-infectives?

Sialendoscopes enter the US through the 510(k) route under product code GCJ and 21 CFR 876.1500, a pathway Karl Storz used for its sialoendoscope family cleared on 1 November 2001.

The FDA 510(k) record K012527 shows that clearance, and later salivary gland infection tools followed the same route: Sialo Technology’s balloon dilatation catheter on 14 May 2008, its modular endoscope on 18 August 2010 and Cook’s NCircle and NGage stone extractors on 6 July 2012. In Europe, the same devices now need CE marking under the Medical Device Regulation. On the drug side, salivary gland infection treatment relies on long-generic antibiotics approved through abbreviated applications, so regulation shapes supply and price more than innovation. In England, NICE guidance HTG140 on therapeutic sialendoscopy, published 23 May 2007, still frames commissioning, and mumps remains a notifiable disease.

Which companies supply sialendoscopes, stone baskets and generic antibiotics for salivary gland infection?

Douglas Insights estimates Karl Storz holds a 41.3% share of the USD 30.0 million sialendoscopy hardware pool inside the salivary gland infection market, and the top three device suppliers together hold 68.7%.

Karl Storz’s lead rests on its reusable sialendoscope range and the ORL portfolio it has built for more than 75 years. Cook Medical, at an estimated 14.8%, launched its salivary duct access line on 18 March 2013, adding dilators, introducers and nitinol baskets. Polydiagnost, at 12.6%, is a 14-person Bavarian maker whose modular micro-endoscopes signed a global distribution deal with Sialo on 17 October 2007. Sialo Technology holds about 6.9% through disposables. Olympus sells ENT video towers that many sialendoscopy rooms plug into, a wider installed base covered in the Hospital Endoscopy Equipment Market study, although its September 2024 ENT showcase featured rhinolaryngoscopes rather than salivary scopes. In drugs, no single generic maker controls salivary gland infection volume, and the 30 July 2026 mumps signal lifts demand for supportive care rather than antivirals, since no approved mumps antiviral exists.

What would salivary gland infection revenue look like by 2035 under faster mumps or slower sialendoscopy adoption?

The base case reaches USD 695.0 million in 2035 on 2.41% volume and 2.12% price growth. The slower case, 1.38% volume and 1.27% price, ends at USD 577.8 million; the faster case, 3.33% and 2.94%, ends at USD 823.4 million.

The slower case assumes mumps returns to the low 2025 run-rate seen in England and sialendoscopy stays confined to academic centres. The faster case assumes the 71.4% quarterly jump reported on 30 July 2026 marks the start of an adult outbreak cycle in Europe and that China’s mumps notifications climb back toward 300,358 a year. Add one point to annual episode growth and 2035 salivary gland infection revenue rises by USD 71.0 million; remove one point and it falls by USD 64.9 million. Other forecasters put salivary gland infection growth anywhere from 3.5% to 9.2% a year; the Douglas Insights 4.58% lands low in that spread because it prices episodes, not branded drugs.

Douglas Exclusive: the sialadenitis treatment pathway index

The index scores ten countries on how salivary gland infection episodes end: antibiotics and conservative care alone, gland-preserving procedures, or surgery.

The preservation ratio is gland-preserving episodes divided by all procedural episodes, times 100. Germany scores 62.9 and India 15.1; the ten-country median is 46.7. The finding is that procedure mix, not incidence, explains most of the spread in salivary gland infection value per episode: countries above 55 already run sialendoscopy as the default for stones, while countries below 35 still remove the gland. Each 10-point rise in a country’s ratio lifts its average episode value by about 6%, because a sialendoscopy replaces a cheaper antibiotic-only pathway more often than it replaces surgery.

What methodology turns 1.339 million sialadenitis episodes into a priced market?

Five regional models build 1.339 million salivary gland infection episodes and price each one at a regional average. Episode rates per 100,000 run 29.6 in North America, 27.3 in Europe, 17.9 in Asia Pacific, 14.2 in Latin America and 8.1 in the Middle East and Africa.

Inputs: 24 sourced documents, including Danish register rates, US claims procedure rates, ECDC, UKHSA, CDC and China CDC mumps counts, and FinnGen’s 7,943 coded sialoadenitis cases. Receipt: 1.339 million × USD 331.7 = USD 444.1 million. Cross-check one: Europe’s implied obstructive rate of 6.91 per 100,000 sits 5.0% below the Danish confirmed-case rate of 7.27. Cross-check two: the US surgery share in the index implies 1.60 sialadenectomies per 100,000, 11.8% above the 1.43 claims rate for 2013. Regional values sum to the global figure within USD 0.1 million.

Sources

1. UK Health Security Agency Laboratory confirmed cases of measles, mumps and rubella, England: January to March 2026 (2026)
2. US CDC Mumps cases and outbreaks (2026)
3. ECDC Mumps annual epidemiological report for 2023 (2025)
4. US FDA 510(k) K012527 KSEA sialoendoscopes and accessories (2001)
5. American Family Physician (AAFP) Salivary gland disorders (2014)
6. Eur Arch Otorhinolaryngol Incidence of sialolithiasis in Denmark: a nationwide population-based register study (2017)
7. The Laryngoscope Rates of sialoendoscopy and sialoadenectomy in 5,111 adults with private insurance (2018)
8. NICE Therapeutic sialendoscopy (HTG140) (2007)